StockNews.com Initiates Coverage on BioLineRx (NASDAQ:BLRX)

StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX – Get Rating) in a research report released on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

BioLineRx Stock Performance

Shares of NASDAQ BLRX opened at $0.61 on Thursday. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.15. BioLineRx has a 1 year low of $0.55 and a 1 year high of $1.98. The firm’s 50-day moving average is $0.63 and its 200-day moving average is $0.79.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC boosted its stake in BioLineRx by 195.6% during the 3rd quarter. Virtu Financial LLC now owns 46,168 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 30,551 shares during the last quarter. PVG Asset Management Corp bought a new position in BioLineRx during the 3rd quarter worth approximately $44,000. Apollon Wealth Management LLC bought a new position in BioLineRx during the 3rd quarter worth approximately $45,000. Renaissance Technologies LLC boosted its stake in BioLineRx by 49.1% during the 3rd quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 22,478 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in BioLineRx by 152.7% during the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 71,134 shares during the last quarter. Institutional investors own 18.15% of the company’s stock.

BioLineRx Company Profile

(Get Rating)

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is a immunotherapy treatment used fro multiple solid tumors. The company was founded in 2003 and is headquartered in Modi’in, Israel.